AngeloHumbertoParedesMD

PubMed

• Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
  Mayur Brahmania, Alexander Kuo, Elliot B Tapper, Michael Volk, Jennifer M Vittorio, Marwan Ghabril, Timothy Morgan, Fasiha Kanwal, Neehar D Parikh, Paul Martin, Shivan...> ;Hepatology. 2024 Mar 27
• 1 citations
  Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver Disease.
  Peter C. Johnson, Anthony A. Cochet, Rosco S. Gore, Stephen A. Harrison, John Magulick, James K. Aden, Angelo H. Paredes> ;The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi. 2021 Sep 25
• 98 citations
  Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
  Stephen A. Harrison, Samer Gawrieh, Katharine Roberts, Christopher J. Lisanti, Ryan B. Schwope, Katherine M. Cebe, Valérie Paradis, Pierre Bedossa, Jennifer Whitehead,...> ;Journal of Hepatology. 2021 Mar 18
• 138 citations
  Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
  Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy, Mustafa R. Bashir, Angelo H. Paredes, Juan P. Frias, Ziad Younes, James F. Trotter, Nadege Gunn, Sam E. Moussa, Anita...> ;Gastroenterology. 2021 Jan 1
• 169 citations
  Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
  Naga Chalasani, M. Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary E. Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell L. Shiffman, Arun J. S...> ;Gastroenterology. 2020 Apr 1
• 329 citations
  FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective der...
  Philip N. Newsome, Magali Sasso, Jonathan J Deeks, Angelo H. Paredes, Jérôme Boursier, Wah-Kheong Chan, Yusuf Yilmaz, Sébastien Czernichow, Ming-Hua Zheng, Vincent Wai...> ;The Lancet. Gastroenterology & Hepatology. 2020 Feb 3
• The transcontinental variability of nonalcoholic fatty liver disease.
  Claudia P Oliveira, Angelo Paredes, Mohammed Siddiqui, Lawrence Serfaty, Abhijit Chowdhury, Jose Tadeu Stefano, Denise Siqueira Vanni, Sherry Boyett, Arun J Sanyal> ;Hepatoma Research. 2020 Jan 1
• 7 citations
  One-hour Recovery Time in Subjects Undergoing Percutaneous Liver Biopsy: A Quality Improvement and Patient Safety Project.
  Billy-Joe Liane, Guy Dooley, Sonali Sarkar, Angelo H. Paredes, Amilcar Morales‐Cardona> ;Cureus. 2019 Sep 29
• 14 citations
  Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
  Sumit Kar, Sabina Paglialunga, Sharon H. Jaycox, Rafiq Islam, Angelo H. Paredes> ;Plos One. 2019 Jul 10
• 56 citations
  Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
  Mary E. Rinella, James F. Trotter, Manal F. Abdelmalek, Angelo H. Paredes, Margery A. Connelly, Mark J. Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, Stephen A. ...> ;Journal of Hepatology. 2019 Apr 1
• 166 citations
  NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
  Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes, James F. Trotter, Mustafa R. Bashir, Cynthia D. Guy, Rajarshi Banerjee, Mark J. Jaros, Sandra Owers, Bryan Ba...> ;Hepatology. 2020 Apr 1
• 48 citations
  Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a p...
  Stephen A. Harrison, Andrea Dennis, Martine M. Fiore, Matt Kelly, Catherine Kelly, Angelo H. Paredes, Jennifer Whitehead, Stefan Neubauer, Peter G. Traber, Rajarshi Ba...> ;Plos One. 2018 Sep 7
• 278 citations
  NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
  Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek, James F. Trotter, Angelo H. Paredes, Hays Arnold, Marcelo Kugelmas, Mustafa R. Bashir, Mark J. Jaros, Lei Li...> ;Lancet. 2018 Mar 24
• 4 citations
  Gastric Outlet Obstruction due to Gastrointestinal Amyloidosis.
  Jared Cohen, Jong An, Alexander W. Brown, Darren Spearman, Angelo H. Paredes> ;Journal of Gastrointestinal Surgery. 2017 Mar 1
• 7 citations
  Utility of Evaluating HCV in an Uninsured Population
  Indira Donepudi, Angelo H. Paredes, Sarah Hubbard, Chadi Awad, Richard K. Sterling> ;Digestive Diseases and Sciences. 2015 Apr 1
• 2 citations
  Splenic laceration following ERCP
  Angelo H. Paredes, A. M. Williams, A. E. Vertrees, C. Womeldorph> ;Endoscopy. 2013 Aug 14
• 4 citations
  Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exercise.
  H M D Angelo Paredes, Dawn M. Torres, Stephen A. Harrison> ;Clinical Liver Disease. 2012 Sep 1
• 49 citations
  Nonalcoholic Fatty Liver Disease
  Angelo H. Paredes, Dawn M. Torres, Stephen A. Harrison> ;Clinics in Liver Disease. 2012 May 1
• Radiology corner. Case 34: Aspergilloma.
  Massimo Federico, Bridget Cunningham, Angelo H. Paredes, Dara Lee, Les R. Folio> ;Military Medicine. 2009 Apr 1
• 52 citations
  Drug-induced liver injury in 2007.
  William Norris, Angelo H. Paredes, James H. Lewis> ;Current Opinion in Gastroenterology. 2008 May 1
• 17 citations
  Terbinafine-Induced Acute Autoimmune Hepatitis in the Setting of Hepatitis B Virus Infection:
  Angelo H. Paredes, James H. Lewis> ;The Annals of Pharmacotherapy. 2007 May 1
• Join now to see all